Checkmate Pharmaceuticals is conducting a multi-indication study of vidutolimod (CMP-001) in combination with cemiplimab for the treatment of PD-1 refractory cutaneous squamous cell carcinoma (CSCC), Merkel cell carcinoma (MCC) and first-line CSCC. Non-melanoma skin cancer refers to any cancer that forms in the basal, squamous or Merkel cells of the skin. According to the published literature, CSCC is the second most common form of skin cancer behind basal cell carcinoma. As many as 700,000 people each year will develop CSCC in the United States. Sun exposure is a significant risk factor, and development of CSCC is associated with more sun exposure, sunburns, and indoor tanning. MCC is a rare skin cancer that originates in neuroendocrine cells of the skin. There are approximately 2,500 new cases of MCC in the United States annually, and the incidence is rising about 5 – 10% per year. MCC generally occurs on sun-exposed regions of skin, and many cases appear to be associated with a novel Merkel Cell polyoma virus. Treatments for non-melanoma skin cancers can include surgery, radiation therapy with or without chemotherapy, and PD-1 blocking antibodies.
CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
A Phase 2 study of CMP-001 intratumoral (IT) and cemiplimab intravenous (IV) administered to participants with certain types of advanced or metastastic cancer.
The study is designed to determine the confirmed objective response (ORR) for treatment with vidutolimod in combination with cemiplimab in participants with certain types of advanced or metastastic non-melanoma skin cancer.
To learn more about this clinical trial or to view a list of active trial sites, please visit:
Vidutolimod is an investigational immunotherapy being evaluated in clinical studies and has not been approved by the FDA or any other agency. Clinical trials are designed to evaluate the safety and efficacy of investigational therapies. Please consult your doctor about your eligibility and the benefits and risks of participating in our trials.